Verve Therapeutics Inc VERV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV
-
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
-
Shareholders that lost money on Verve Therapeutics, Inc. (VERV) should contact The Gross Law Firm about pending Class Action - VERV
-
Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
-
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm
Trading Information
- Previous Close Price
- $4.72
- Day Range
- $4.73–5.02
- 52-Week Range
- $4.31–20.12
- Bid/Ask
- $5.00 / $5.02
- Market Cap
- $423.12 Mil
- Volume/Avg
- 996,142 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 255
- Website
- https://www.vervetx.com
Comparables
Valuation
|
Metric
|
VERV
|
RCKT
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 14.90 |
Price/Book Value | 0.73 | 3.80 | 2.73 |
Price/Sales | 17.16 | — | 6.58 |
Price/Cash Flow | — | — | 14.11 |
Price/Earnings
VERV
RCKT
UTHR
Financial Strength
|
Metric
|
VERV
|
RCKT
|
UTHR
|
|---|---|---|---|
Quick Ratio | 14.34 | 7.42 | 3.92 |
Current Ratio | 14.64 | 7.79 | 4.35 |
Interest Coverage | — | −143.43 | 22.67 |
Quick Ratio
VERV
RCKT
UTHR
Profitability
|
Metric
|
VERV
|
RCKT
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −23.76% | −41.09% | 16.95% |
Return on Equity (Normalized) | −30.33% | −46.72% | 20.53% |
Return on Invested Capital (Normalized) | −30.18% | −47.69% | 16.62% |
Return on Assets
VERV
RCKT
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Skqzmrymmm | Qtgn | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lttkqjkg | Fhmbyll | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jqbrsnhhq | Slzjb | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wlfxjpvhm | Tvbhtcz | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Nstnxlcrs | Pvfb | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Dnhkbwmtg | Hrcg | $28.5 Bil | |||
| Moderna Inc
MRNA
| Whhcnvcl | Grnqh | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Cnssjnh | Mwjwz | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xbpxsfvhv | Qccdyf | $13.0 Bil | |||
| Incyte Corp
INCY
| Dyjjckvx | Sfhklt | $12.9 Bil |
United States